NAS:RDNT (USA) Also trade in: Germany

RadNet Inc

$ 12.48 -0.19 (-1.5%)
Volume: 69,467 Avg Vol (1m): 322,417
Market Cap $: 627.01 Mil Enterprise Value $: 1.37 Bil
P/E (TTM): 17.13 P/B: 4.54
Earnings Power Value -25.09
Net Current Asset Value -23.69
Tangible Book -6.65
Projected FCF 2.07
Median P/S Value 5.59
Graham Number 0
Peter Lynch Value 3.9
DCF (FCF Based) -6.96
DCF (Earnings Based) 7.81
1Y (-%)

Financial Strength : 4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.02
Cash-To-Debt ranked lower than
99.62% of 261 companies
in the Diagnostics & Research industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
RDNT: 0.02
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0, Med: 0, Max: 0.08
Current: 0.02
0
0.08
Equity-to-Asset 0.09
Equity-to-Asset ranked lower than
94.56% of 239 companies
in the Diagnostics & Research industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
RDNT: 0.09
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.85, Med: -0.15, Max: 0.12
Current: 0.09
-0.85
0.12
Debt-to-Equity 4.97
Debt-to-Equity ranked lower than
98.78% of 164 companies
in the Diagnostics & Research industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
RDNT: 4.97
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -7270.33, Med: -3.12, Max: 1073.18
Current: 4.97
-7270.33
1073.18
Debt-to-EBITDA 3.76
Debt-to-EBITDA ranked lower than
84.48% of 116 companies
in the Diagnostics & Research industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
RDNT: 3.76
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 3.76, Med: 5.12, Max: 5.91
Current: 3.76
3.76
5.91
Interest Coverage 1.00
Interest Coverage ranked lower than
96.93% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 15605.52, Med: 76.01, Min: 0.54
RDNT: 1
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 0.79, Med: 0.96, Max: 1.3
Current: 1
0.79
1.3
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.98
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC 5.76%
WACC 4.92%

Profitability & Growth : 7/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 4.50
Operating Margin ranked higher than
57.44% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
RDNT: 4.5
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 3.56, Med: 6.82, Max: 8.51
Current: 4.5
3.56
8.51
Net Margin % 3.53
Net Margin ranked higher than
55.60% of 241 companies
in the Diagnostics & Research industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
RDNT: 3.53
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -2.48, Med: 0.56, Max: 9.25
Current: 3.53
-2.48
9.25
ROE % 34.18
ROE ranked higher than
90.08% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
RDNT: 34.18
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 0.1, Med: 34.17, Max: 52.1
Current: 34.18
0.1
52.1
ROA % 3.33
ROA ranked higher than
59.92% of 262 companies
in the Diagnostics & Research industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
RDNT: 3.33
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -2.52, Med: 0.58, Max: 9
Current: 3.33
-2.52
9
ROC (Joel Greenblatt) % 27.32
ROC (Joel Greenblatt) ranked higher than
66.41% of 259 companies
in the Diagnostics & Research industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
RDNT: 27.32
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 14.94, Med: 19.15, Max: 27.32
Current: 27.32
14.94
27.32
3-Year Total Revenue Growth Rate 6.40
3-Year Revenue Growth Rate ranked lower than
57.14% of 182 companies
in the Diagnostics & Research industry.
Industry Max: 371, Med: 4.8, Min: -100
RDNT: 3.8
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 2.4, Med: 7.9, Max: 25.5
Current: 3.8
2.4
25.5
3-Year Total EBITDA Growth Rate 9.80
3-Year EBITDA Growth Rate ranked lower than
69.10% of 178 companies
in the Diagnostics & Research industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
RDNT: 7.1
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 6.7, Max: 134.5
Current: 7.1
0
134.5
3-Year EPS w/o NRI Growth Rate 57.20
3-Year EPS w/o NRI Growth Rate ranked higher than
86.50% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 138.7, Med: 10.1, Min: -301
RDNT: 57.2
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -40.1, Max: 57.2
Current: 57.2
0
57.2

» RDNT's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:RDNT

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 621512    SIC : 8071
Compare NAS:HSKA SHSE:603716 NAS:SRDX NAS:VIVO BSP:PARD3 HKSE:02393 NAS:QTNT SZSE:300639 OHEL:REG1V SZSE:300396 XBRU:BCART SZSE:300289 LSE:IDHC BSP:AALR3 AMEX:SENS NAS:OXFD TSE:4282 SZSE:300439 SZSE:002932 OSTO:CEVI
Traded in other countries PQIA.Germany
Address 1510 Cotner Avenue, Los Angeles, CA, USA, 90025
RadNet Inc provides outpatient diagnostic imaging services in the United States. Its centers provide physicians with imaging capabilities, including magnetic resonance imaging, computed tomography, positron emission tomography, mammography, ultrasound, and X-ray procedures. RadNet's centers are concentrated in specific geographies, including California, Delaware, Florida, Maryland, New Jersey, New York, and Rhode Island. Most of the firm's centers offer various combinations of imaging technologies. RadNet's revenue primarily comes from fees charged for the services performed at these centers.

Ratios

Current vs industry vs history
PE Ratio (TTM) 17.13
PE Ratio ranked lower than
75.22% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35, Min: 0.33
RDNT: 17.13
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 1.44, Med: 23.48, Max: 99999999.99
Current: 17.13
1.44
99999999.99
Forward PE Ratio 31.65
Forward P/E ranked lower than
100.00% of 40 companies
in the Diagnostics & Research industry.
Industry Max: 78.74, Med: 9999, Min: 11.64
RDNT: 31.65
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 17.13
PE without NRI ranked lower than
74.34% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35.56, Min: 0.34
RDNT: 17.13
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 1.44, Med: 23.48, Max: 99999999.99
Current: 17.13
1.44
99999999.99
Price-to-Owner-Earnings 19.48
Price-to-Owner-Earnings ranked lower than
100.00% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 1523.53, Med: 36.75, Min: 4.91
RDNT: 19.48
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 13.08, Med: 21.1, Max: 39.13
Current: 19.48
13.08
39.13
PB Ratio 4.54
PB Ratio ranked lower than
77.55% of 245 companies
in the Diagnostics & Research industry.
Industry Max: 270, Med: 4.02, Min: 0.15
RDNT: 4.54
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 4, Med: 7.96, Max: 715.38
Current: 4.54
4
715.38
PS Ratio 0.61
PS Ratio ranked higher than
94.78% of 230 companies
in the Diagnostics & Research industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
RDNT: 0.61
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.07, Med: 0.27, Max: 0.79
Current: 0.61
0.07
0.79
Price-to-Operating-Cash-Flow 5.12
Price-to-Operating-Cash-Flow ranked higher than
94.85% of 97 companies
in the Diagnostics & Research industry.
Industry Max: 1739.7, Med: 19.94, Min: 0.35
RDNT: 5.12
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 0.56, Med: 2.76, Max: 8.5
Current: 5.12
0.56
8.5
EV-to-EBIT 15.40
EV-to-EBIT ranked higher than
66.10% of 118 companies
in the Diagnostics & Research industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
RDNT: 15.4
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: 9.3, Med: 16.5, Max: 33.7
Current: 15.4
9.3
33.7
EV-to-EBITDA 7.60
EV-to-EBITDA ranked higher than
84.09% of 132 companies
in the Diagnostics & Research industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
RDNT: 7.6
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: 5.1, Med: 7.3, Max: 10.5
Current: 7.6
5.1
10.5
EV-to-Revenue 1.36
EV-to-Revenue ranked higher than
86.78% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
RDNT: 1.36
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.9, Med: 1.1, Max: 1.6
Current: 1.36
0.9
1.6
PEG Ratio 5.45
PEG Ratio ranked lower than
100.00% of 48 companies
in the Diagnostics & Research industry.
Industry Max: 128.13, Med: 3.26, Min: 0.32
RDNT: 5.45
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0.16, Med: 1.44, Max: 99999999.99
Current: 5.45
0.16
99999999.99
Shiller PE Ratio 49.50
Shiller PE Ratio ranked lower than
84.62% of 39 companies
in the Diagnostics & Research industry.
Industry Max: 459.08, Med: 52.49, Min: 10.19
RDNT: 49.5
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 41.32, Med: 90.91, Max: 763
Current: 49.5
41.32
763
Current Ratio 0.72
Current Ratio ranked lower than
80.80% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
RDNT: 0.72
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.15, Med: 1.09, Max: 1.9
Current: 0.72
0.15
1.9
Quick Ratio 0.72
Quick Ratio ranked lower than
70.80% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
RDNT: 0.72
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.15, Med: 1.09, Max: 1.9
Current: 0.72
0.15
1.9
Days Sales Outstanding 56.36
Days Sales Outstanding ranked higher than
50.00% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 521.64, Med: 67.51, Min: 1
RDNT: 56.36
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 55.74, Med: 68.57, Max: 80.12
Current: 56.36
55.74
80.12
Days Payable 72.46
Days Payable ranked lower than
100.00% of 187 companies
in the Diagnostics & Research industry.
Industry Max: 981.81, Med: 63.34, Min: 1
RDNT: 72.46
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 12.98, Med: 22.72, Max: 72.46
Current: 72.46
12.98
72.46

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -1.70
3-Year Share Buyback Rate ranked higher than
61.11% of 180 companies
in the Diagnostics & Research industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
RDNT: -1.7
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -20.1, Med: -2.1, Max: 0.8
Current: -1.7
-20.1
0.8

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 6.05
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
100.00% of 75 companies
in the Diagnostics & Research industry.
Industry Max: 449, Med: 2.41, Min: 0.47
RDNT: 6.05
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.56, Med: 6.72, Max: 128.5
Current: 6.05
0.56
128.5
Price-to-DCF (Earnings Based) 1.60
Price-to-Intrinsic-Value-DCF (Earnings Based) ranked lower than
100.00% of 17 companies
in the Diagnostics & Research industry.
Industry Max: 6.59, Med: 1.86, Min: 0.72
RDNT: 1.6
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
Price-to-Intrinsic-Value-DCF (Earnings Based) range over the past 10 years
Min: 0.16, Med: 1.33, Max: 2.73
Current: 1.6
0.16
2.73
Price-to-Median-PS-Value 2.24
Price-to-Median-PS-Value ranked lower than
86.01% of 193 companies
in the Diagnostics & Research industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
RDNT: 2.24
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.24, Med: 0.94, Max: 3.6
Current: 2.24
0.24
3.6
Price-to-Peter-Lynch-Fair-Value 3.21
Price-to-Peter-Lynch-Fair-Value ranked lower than
100.00% of 30 companies
in the Diagnostics & Research industry.
Industry Max: 15.31, Med: 2.01, Min: 0.83
RDNT: 3.21
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.17, Med: 1.19, Max: 5.06
Current: 3.21
0.17
5.06
Earnings Yield (Joel Greenblatt) % 6.51
Earnings Yield (Greenblatt) ranked higher than
84.91% of 265 companies
in the Diagnostics & Research industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
RDNT: 6.51
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: 3, Med: 6.1, Max: 10.8
Current: 6.51
3
10.8
Forward Rate of Return (Yacktman) % 4.69
Forward Rate of Return ranked lower than
84.29% of 70 companies
in the Diagnostics & Research industry.
Industry Max: 7802.99, Med: 8.45, Min: -35.9
RDNT: 4.69
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: -13.1, Med: 1.9, Max: 22.9
Current: 4.69
-13.1
22.9

More Statistics

Revenue (TTM) (Mil) $ 1,015.3
EPS (TTM) $ 0.73
Beta 0.63
Volatility % 51.38
52-Week Range $ 9.97 - 16.54
Shares Outstanding (Mil) 50.08

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y